Hepion CMO Todd Hobbs resigns; Stephen Harrison appointed Consultant Medical Director

Hepion Pharmaceuticals, Inc.

Dr. Todd Hobbs resigned as CMO effective September 29, 2023; resignation not due to any disagreement with the Company.
Company appointed Dr. Stephen Harrison as Consultant Medical Director; he chairs the Scientific Advisory Board.
Dr. Harrison previously served as Consultant Medical Director from Oct 2019 to Feb 2021; leads Pinnacle Clinical Research.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stephen Harrison

Consultant Medical Director

HEPA · Hepion Pharmaceuticals, Inc.

Effective: 2023-09-06
Filed: September 6, 2023, 7:59 PM ET

On September 6, 2023, the Company appointed Stephen Harrison, M.D., the Company’s current Chairman of the Company’s Scientific Advisory Board, as Consultant Medical Director.

Departed

Todd Hobbs

Chief Medical Officer

HEPA · Hepion Pharmaceuticals, Inc.

Effective: 2023-09-29
Filed: September 6, 2023, 7:59 PM ET

On August 30, 2023, Dr. Todd Hobbs, the Chief Medical Officer (“CMO”), of Hepion Pharmaceuticals, Inc. (the “Company”) provided notice to the Company of his resignation as CMO, effective September 29, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Harrison was appointed as Consultant Medical Director at Hepion Pharmaceuticals, Inc..

Action: appointed
Role: Consultant Medical Director

Exact text from the filing

On September 6, 2023, the Company appointed Stephen Harrison, M.D., the Company’s current Chairman of the Company’s Scientific Advisory Board, as Consultant Medical Director.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Todd Hobbs resigned as Chief Medical Officer at Hepion Pharmaceuticals, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On August 30, 2023, Dr. Todd Hobbs, the Chief Medical Officer (“CMO”), of Hepion Pharmaceuticals, Inc. (the “Company”) provided notice to the Company of his resignation as CMO, effective September 29, 2023.

View on SEC.gov

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-098668

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.